Sino

Canacol Energy Ltd. Announces Resignation of Juan Argento and Appointment of Valentina Garbarini to Board of Directors

Retrieved on: 
Wednesday, October 18, 2023
Business administration, Universidad Iberoamericana, Social responsibility, CNE, Sino, Telecommunications, Corporation, Family, Bentley University, TSX, Marketing, Management

CALGARY, Alberta, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) announces the resignation of Mr. Juan Argento and is pleased to announce that Ms. Valentina Garbarini has been appointed to the Board of Directors as his replacement.

Key Points: 
  • CALGARY, Alberta, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) announces the resignation of Mr. Juan Argento and is pleased to announce that Ms. Valentina Garbarini has been appointed to the Board of Directors as his replacement.
  • Mr. Argento has served on the Board of Directors since February 2021, originally as a nominee of one of the Corporation's principal shareholders.
  • The Corporation has accepted the nomination of and has appointed Ms. Garbarini to the Board of Directors of the Corporation.
  • The Board of Directors looks forward to working together with her in the coming years and benefiting from her experience.

Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

Retrieved on: 
Thursday, May 25, 2023
NASH, File, New Drug Application, NDA, Pharmacokinetics, Tai, Sino Biopharmaceutical Limited, Euronext Paris, Investigational New Drug, Patient, Overseas, Fatty liver disease, Sino, IND, NMPA, Pharmaceutical industry, Chinese

Frederic Cren, CEO and cofounder of Inventiva, stated: “We are extremely pleased by this positive feedback from the NMPA, which allows our lead compound to advance into a Phase III clinical trial in NASH in mainland China.

Key Points: 
  • Frederic Cren, CEO and cofounder of Inventiva, stated: “We are extremely pleased by this positive feedback from the NMPA, which allows our lead compound to advance into a Phase III clinical trial in NASH in mainland China.
  • This is an important milestone for us and our partner Sino Biopharm, and brings new opportunities for patients affected by NASH in China to participate in the global NATiV3 Phase III clinical trial.
  • We are looking to successfully develop lanifibranor with Sino Biopharm and potentially commercialize in China the first oral treatment for patients with NASH.”
    Philip Duong, Head of Overseas BD & Alliance, Sino Biopharm: “We are delighted to have received the IND approval from the Chinese NMPA.
  • CTTQ will be responsible for all costs linked to lanifibranor development in China.

American Wealth Mining Corp. Update on New Energy’s Signing of MOU for a Partnership to Develop Over 300 EV Charging Stations in The New Territories of Hong Kong

Retrieved on: 
Wednesday, February 22, 2023
MOU, New Territories, Partnership, OTC, AWM, EVS, Sino, EV, Rare-earth element, Renewable energy, Smart village, New energy

Ltd. (“Sino Express”) to develop the “Smart Village Electric Vehicle (EV) Charging Station Business Plan” (“Smart Village”).

Key Points: 
  • Ltd. (“Sino Express”) to develop the “Smart Village Electric Vehicle (EV) Charging Station Business Plan” (“Smart Village”).
  • Over the next five years, the Smart Village project targets to create over 300 electric vehicle (EV) charging stations in rural areas located in the New Territories of Hong Kong – comprising of 600-1,200 ultra-fast EV charging chargers and 5,000 – 7,000 medium-speed EV charging chargers.
  • This region covers a large proportion of Hong Kong's land area, accounting for 86.2%, and is home to about half of the city's population.
  • In the subsequent phase, New Energy will invest in constructing big EV charging stations, and Sino Express will become the exclusive operator of these stations in Hong Kong.

Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China

Retrieved on: 
Wednesday, September 21, 2022
Adult, MPS, Chronic liver disease, Lists of diseases, Fatty liver disease, Therapy, ISIN, Cirrhosis, Risk, FDA, Food, Abivax, Prevalence, Chia, NASH, Liver disease, Company, Sino, United, Liver cancer, Sino Biopharmaceutical Limited, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Factor X, Breakthrough therapy, Mucopolysaccharidosis, CEO, United Kingdom, Biology, Nasdaq, Leadership, Degenerative disease, Pharmacology, VI, Agreement, IVA, PPAR, Research, Pharmacokinetics, Motivation, Computational chemistry, AbbVie, Respiratory system, Gene expression, Pharmaceutical industry, Euronext Paris

We are particularly proud of partnering with Sino Biopharm, a company with a strong presence in the hepatology field and a clear motivation and strategy to make lanifibranor a potential treatment option for patients with NASH in Greater China.

Key Points: 
  • We are particularly proud of partnering with Sino Biopharm, a company with a strong presence in the hepatology field and a clear motivation and strategy to make lanifibranor a potential treatment option for patients with NASH in Greater China.
  • Theresa Tse, Chairwoman, Sino Biopharm: This agreement is further evidence of Sino Biopharms commitment to seeking innovation, in one of our core therapeutics areas, liver disease.
  • Under the terms of the Agreement, Inventiva has the potential to receive up to $290 million of clinical, regulatory and commercial milestone payments.
  • The collaboration with Inventiva is managed by invoX Pharma Limited (invoX), a wholly owned subsidiary of Sino Biopharm, headquarter in the United Kingdom.

invoX Pharma Extends Tender Offer to Acquire F-star Therapeutics, Inc.

Retrieved on: 
Thursday, August 4, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Personal Information Agent, Sino Biopharmaceutical Limited, CD137, Security (finance), Annual report, Acquisition, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Letter, LLP, Marketing, Sino, PJT Partners, Shearman & Sterling, NASDAQ, Communication, THE, HKEX, TIME, Computershare, Schedule, CNS, U.S. Securities and Exchange Commission, Safety, Maintenance, President's Pay Agent, Technology, Research, Drug development, Time, COMMON, Forward-looking statement, Universal asynchronous receiver-transmitter, Cancer, Therapy, R, Drug discovery, Schedule TO, P.C, Morgan Stanley, Eastern Time Zone, Degenerative disease, Patent, Risk, Immunotherapy, SEC, Fine chemical, Online shopping, Pharmaceutical industry, Bookkeeping

The tender offer is now scheduled to expire at 05:00 p.m., Eastern Time, on September 19, 2022, unless it is further extended.

Key Points: 
  • The tender offer is now scheduled to expire at 05:00 p.m., Eastern Time, on September 19, 2022, unless it is further extended.
  • The tender offer was previously scheduled to expire at one minute after 11:59 P.M., Eastern time, on August 3, 2022.
  • The tender offer is being extended in order to allow additional time for the satisfaction of the regulatory conditions to the offer.
  • All terms and conditions of the tender offer remain unchanged during the extension period.

SINO AMERICAN OIL CORP ACQUIRES TRITIUM INC OF ALBERTA, CANADA

Retrieved on: 
Tuesday, July 26, 2022
Tritium, Acquisition, Time, GLOBE, Water, U.S. Securities and Exchange Commission, Forward-looking statement, Ownership, Technology, Mission statement, Company, Security (finance), EFS, WTI, Sino, Risk, OTC, Oil

CHEYENNE, WY, July 26, 2022 (GLOBE NEWSWIRE) -- Sino American Oil Corp (OTC PINK: OILY), announces that it has signed a definite acquisition agreement to acquire 100% interest in oil services technology company, Tritium Inc of Alberta, Canada.

Key Points: 
  • CHEYENNE, WY, July 26, 2022 (GLOBE NEWSWIRE) -- Sino American Oil Corp (OTC PINK: OILY), announces that it has signed a definite acquisition agreement to acquire 100% interest in oil services technology company, Tritium Inc of Alberta, Canada.
  • This technology is currently installed and operational at the Base Element Energy Inc. facility in Cynthia, Alberta, Canada terminal which is now 22% owned by SINO.
  • SINO is currently updating its filings to remain fully compliant with the Securities regulators of both the US and Canada.
  • SINO American Oil Corp is a Wyoming incorporated company that consolidates best of breed technologies in the oil services and technology sectors and creates opportunities for small to mid-sized players to scale by providing capital, management skill, expansion capabilities and additional customers.

invoX Pharma Commences Tender Offer for F-star Therapeutics, Inc.

Retrieved on: 
Friday, July 8, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Acquisition, Sino Biopharmaceutical Limited, Hart–Scott–Rodino Antitrust Improvements Act, Schedule, Tripura Merger Agreement, Projection, Research, Marketing, Sale, Expiration, Personal Information Agent, Forward-looking statement, Attempted purchase of Time Warner Cable by Comcast, U.S. Securities and Exchange Commission, Computershare, Sino, Communication, HKEX, Plan, SEC, Degenerative disease, NASDAQ, Time, Eastern Time Zone, President's Pay Agent, Nature, Agreement, Holding company, Cryptocurrency, Airline, Security (finance), Online shopping

invoX, Sino Biopharm and Purchaser have filed a tender offer statement on Schedule TO with the United States Securities and Exchange Commission (the SEC).

Key Points: 
  • invoX, Sino Biopharm and Purchaser have filed a tender offer statement on Schedule TO with the United States Securities and Exchange Commission (the SEC).
  • The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer.
  • As soon as practicable following the completion of the tender offer, Purchaser will acquire all remaining F-star shares through a merger at the tender offer price.
  • On July 7, 2022, invoX, Sino Biopharm and Purchaser filed with the SEC a tender offer statement on Schedule TO regarding the tender offer described in this communication.

invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs

Retrieved on: 
Thursday, June 23, 2022
Time, CNS, Security (finance), PD-1, Patent, Therapy, Schedule TO, Drug development, Safety, Degenerative disease, Annual report, Technology, Sino, DLBCL, Company, POC, U.S. Securities and Exchange Commission, Cancer, Forward-looking statement, Research, Letter, Drug discovery, Marketing, THE, WHEN, Acquisition, Offer, Maintenance, SEC, Sino Biopharmaceutical Limited, IO, Personal Information Agent, Patient, CD137, Communication, Schedule, NSCLC, PD-L1, COMMON, TIME, Immunotherapy, Risk, Fine chemical, Generic drug, Pharmaceutical industry

United Kingdom-based invoX is Sino Biopharms international expansion platform, focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics.

Key Points: 
  • United Kingdom-based invoX is Sino Biopharms international expansion platform, focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics.
  • F-star Therapeutics, Inc.is a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives.
  • F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline.
  • Forward-looking statements included in this communication are based on information available to F-star as of the date of this communication.

DGAP-News: Baader Bank hosts its fifth Open Door Day after a two-year period of interruption

Retrieved on: 
Tuesday, June 7, 2022
Sino, Baader Bank AG, B2B, Director, Board, Norma Group, Social, Security (finance)

Following two years of disturbances due to the pandemic, Baader Bank opened its doors to the company headquarters in Unterschleissheim for the fifth time yesterday.

Key Points: 
  • Following two years of disturbances due to the pandemic, Baader Bank opened its doors to the company headquarters in Unterschleissheim for the fifth time yesterday.
  • The contents of the programme of events was primarily targeted to-wards existing clients of Baader Bank, including asset managers, family offices and fund managers in particular.
  • "Baader Bank offers a wide range of capital market services and acts as a partner and B2B platform for its clients.
  • "The open doors at Baader Bank offered many impulses about the current state of the financial industry.

Sino Biological and Ainnocence Partner to Offer Next-Generation CRO Antibody Development Services

Retrieved on: 
Monday, March 28, 2022
Private Securities Litigation Reform Act, ChiNext, Sino, Technology, A-DNA, GLOBE, CRO, Uncertainty, SZSE, Partnership, Antibody, Fine chemical, Vaccine

Rob Burgess, Sino Biologicals Chief Business Officer, stated, The addition of Ainnocences AI-based antibody-antigen binding prediction technology will enable Sino Biological to further enhance its antibody development CRO services offering, thus saving customers precious development time and ensuring antibody-antigen binding affinities that meet their strict demands.We look forward to working with the Ainnocence team to offer next-generation antibody design and development services.

Key Points: 
  • Rob Burgess, Sino Biologicals Chief Business Officer, stated, The addition of Ainnocences AI-based antibody-antigen binding prediction technology will enable Sino Biological to further enhance its antibody development CRO services offering, thus saving customers precious development time and ensuring antibody-antigen binding affinities that meet their strict demands.We look forward to working with the Ainnocence team to offer next-generation antibody design and development services.
  • Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements.
  • In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.
  • Sino Biological and Ainnocence assume no obligation to update these forward-looking statements and do not intend to do so.